辛伐他汀预防单肺通气非心脏手术术后并发症的随机对照试验方案
Prevention HARP 2 试验为英国多中心、随机、双盲、安慰剂对照研究,计划纳入 452 例择期食管切除术、肺叶切除术或全肺切除术的成人患者。患者术前 4 天至术后最多 7 天接受辛伐他汀 80 mg 或匹配安慰剂,主要结局为术后 7 天内术后肺部并发症(PPC)与心肌梗死(MI)的复合结局。
要点
- 辛伐他汀 80 mg 围术期给药,主要看术后 7 天内 PPC 与 MI 复合结局。
- 计划招募 452 例,来自英国 12 个中心,已用他汀者排除。
- 次要结局涵盖临床、安全性与健康经济学指标,并分析血尿样本探索机制。
核心结论
- 该试验将检验辛伐他汀 80 mg 相比安慰剂能否减少择期食管切除术、肺叶切除术或全肺切除术患者的心脏与肺部并发症。
研究设计与样本
- 英国多中心、随机、双盲、安慰剂对照试验,计划在 12 个中心共招募 452 例成人患者。
- 纳入择期食管切除术、肺叶切除术或全肺切除术的成人患者,已使用他汀者被排除。
- 患者随机接受辛伐他汀 80 mg 或匹配安慰剂,术前 4 天至术后最多 7 天给药。
关键数值与推荐
- 主要结局为术后 7 天内 PPC 与 MI 的复合结局。
- 次要结局包括临床结局、安全性结局与健康经济学结局。
- 试验注册号 ISRCTN48095567,注册日期 2016 年 11 月 11 日。
临床怎么用
- 结果将增进对围术期他汀获益的理解并影响临床决策。
- 血尿样本分析可揭示辛伐他汀作用机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pulmonary complications (PPC) and peri-operative myocardial infarction (MI) have a significant impact on the long-term mortality of surgical patients. Patients undergoing one-lung ventilation (OLV) for surgery are at a high risk of developing these complications. These complications could be associated with intensive care unit (ICU) admissions and longer hospital stay with associated resource and economic burden. Simvastatin, a HMG-CoA reductase enzyme inhibitor has been shown to have pleiotropic anti-inflammatory effects as well as being endothelial protective. The benefits of statins have been shown in various observational studies and in small proof-of-concept studies. There is an urgent need for a well-designed, large clinical trial powered to detect clinical outcomes. The Prevention HARP 2 trial will test the hypothesis 'simvastatin 80 mg when compared to placebo will reduce cardiac and pulmonary complications in patients undergoing elective oesophagectomy, lobectomy or pneumonectomy'. METHODS/DESIGN: The Prevention HARP 2 trial is a UK multi-centre, randomised, double-blind, placebo-controlled trial. Adult patients undergoing elective oesophagectomy, lobectomy or pneumonectomy will be eligible. Patients who are already on statins will be excluded from this trial. Patients will be randomised to receive simvastatin 80 mg or matched placebo for 4 days pre surgery and for up to 7 days post surgery. The primary outcome is a composite outcome of PPC and MI within 7 days post surgery. Various secondary outcome measures including clinical outcomes, safety outcomes and health economic outcomes will be collected. The study aims to recruit 452 patients in total across 12 UK sites. DISCUSSION: The results of the Prevention HARP 2 trial should add to our understanding of the benefits of peri-operative statins and influence clinical decision-making. Analysis of blood and urine samples from the patients will provide insight into the mechanism of simvastatin action. TRIAL REGISTRATION: International Standard Randomised Controlled Trials registry, ID: ISRCTN48095567 . Registered on 11 November 2016.
引用
- Shyamsundar M, O'Kane C, Perkins GD, et al. Prevention of post-operative complications by using a HMG-CoA reductase inhibitor in patients undergoing one-lung ventilation for non-cardiac surgery: study protocol for a randomised controlled trial. Trials. 2018. PMID: 30563555. doi:10.1186/s13063-018-3078-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。